Abstract
Parkinsons disease is a neurodegenerative disorder characterized by a progressive neuronal loss affecting preferentially the dopaminergic neurons of the nigrostriatal projection. Transplantation of fetal dopaminergic precursor cells has provided the proof of principle that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Recent years have provided evidence for the existence of neural stem cells with the potential to produce new neurons, particularly of a dopaminergic phenotype, in the adult mammalian brain. Such stem cells have been identified in so called neurogenic brain areas, where neurogenesis is constitutively ongoing, but also in primarily non-neurogenic areas, such as the midbrain and the striatum, where neurogenesis does not occur under normal physiological conditions. We review here presently published evidence to evaluate the concept that endogenous neural stem cells may have the potential to be instrumentalized for a non-invasive cell replacement therapy with autologous neurons to repair the damaged nigrostriatal dopaminergic projection in Parkinsons disease.
Keywords: Parkinson's disease, neurogenesis, stem cells, dopamine, cell therapy, regenerative medicine
CNS & Neurological Disorders - Drug Targets
Title: Adult Neurogenesis and Parkinsons Disease
Volume: 6 Issue: 5
Author(s): Oscar Arias-Carrion, Nils Freundlieb, Wolfgang H. Oertel and Gunter U. Hoglinger
Affiliation:
Keywords: Parkinson's disease, neurogenesis, stem cells, dopamine, cell therapy, regenerative medicine
Abstract: Parkinsons disease is a neurodegenerative disorder characterized by a progressive neuronal loss affecting preferentially the dopaminergic neurons of the nigrostriatal projection. Transplantation of fetal dopaminergic precursor cells has provided the proof of principle that a cell replacement therapy can ameliorate clinical symptoms in affected patients. Recent years have provided evidence for the existence of neural stem cells with the potential to produce new neurons, particularly of a dopaminergic phenotype, in the adult mammalian brain. Such stem cells have been identified in so called neurogenic brain areas, where neurogenesis is constitutively ongoing, but also in primarily non-neurogenic areas, such as the midbrain and the striatum, where neurogenesis does not occur under normal physiological conditions. We review here presently published evidence to evaluate the concept that endogenous neural stem cells may have the potential to be instrumentalized for a non-invasive cell replacement therapy with autologous neurons to repair the damaged nigrostriatal dopaminergic projection in Parkinsons disease.
Export Options
About this article
Cite this article as:
Arias-Carrion Oscar, Freundlieb Nils, Oertel H. Wolfgang and Hoglinger U. Gunter, Adult Neurogenesis and Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2007; 6 (5) . https://dx.doi.org/10.2174/187152707783220875
DOI https://dx.doi.org/10.2174/187152707783220875 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research A Novel Nanoformulation of Ellagic Acid is Promising in Restoring Oxidative Homeostasis in Rat Brains with Alzheimer’s Disease
Current Drug Metabolism Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Role of Nuclear Factor Kappa B (NF-κB) Signalling in Neurodegenerative Diseases: An Mechanistic Approach
Current Neuropharmacology Toxicity of Carbon Nanotubes
Current Drug Metabolism Cubosomes: Innovative Nanostructures for Drug Delivery
Current Drug Delivery Lys203 and Lys382 are Essential for the Proteasomal Degradation of BACE1
Current Alzheimer Research Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Role of Caspases in Activation-Induced Cell Death of Neuroglia
Current Enzyme Inhibition Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase
Current Protein & Peptide Science A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease
Current Pharmaceutical Design The Biology of Neurotrophins, Signalling Pathways, and Functional Peptide Mimetics of Neurotrophins and their Receptors
CNS & Neurological Disorders - Drug Targets Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets Dimerization and Ion Binding Properties of S100P Protein
Protein & Peptide Letters Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Small Heat Shock Proteins: Recent Advances in Neuropathy
Current Neurovascular Research From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research